Page 230 - Read Online

31. Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites 52. Anderson G, Maes M. Bipolar disorder: role of immune‑inflammatory
in brain function and disease. Nat Rev Neurosci 2014;15:771‑85. cytokines, oxidative and nitrosative stress and tryptophan catabolites.
32. Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandin E2 Curr Psychiatry Rep 2015;17:8.
and thromboxane B2 in depression. Prostaglandins Leukot Med 53. Andreazza AC, Kauer‑Sant’anna M, Frey BN, Bond DJ, Kapczinski F,
1983;10:361‑7. Young LT, Yatham LN. Oxidative stress markers in bipolar disorder:
33. Muller N, Myint AM, Schwarz MJ. The impact of neuroimmune a meta‑analysis. J Affect Disord 2008;111:135‑44.
dysregulation on neuroprotection and neurotoxicity in psychiatric 54. Bai YM, Su TP, Li CT, Tsai SJ, Chen MH, Tu PC, Chiou WF.
disorders‑Relation to drug treatment. Dialogues Clin Neurosci Comparison of pro‑inflammatory cytokines among patients with
2009;11:319‑32. bipolar disorder and unipolar depression and normal controls.
34. Muller N, Myint AM, Schwarz MJ. Inflammatory biomarkers and Bipolar Disord 2015;17:269‑77.
depression. Neurotox Res 2011;19:308‑18. 55. Barbosa IG, Nogueira CR, Rocha NP, Queiroz AL, Vago JP,
35. Nishino S, Ueno R, Ohishi K, Sakai T, Hayaishi O. Salivary Tavares LP, Assis F, Fagundes CT, Huguet RB, Bauer ME,
prostaglandin concentrations: possible state indicators for major Teixeira AL, de Sousa LP. Altered intracellular signaling cascades
depression. Am J Psychiatry 1989;146:365‑8. in peripheral blood mononuclear cells from BD patients. J Psychiatr
36. Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, Res 2013;47:1949‑54.
Allen NB, Stuart AL, Hayley AC, Byrne ML, Maes M. So depression 56. Barbosa IG, Rocha NP, Bauer ME, de Miranda AS, Huguet RB,
is an inflammatory disease, but where does the inflammation come Reis HJ, Zunszain PA, Horowitz MA, Pariante CM, Teixeira AL.
from? BMC Med 2013;11:200. Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry
37. Leonard BE. The immune system, depression and the action of Clin Neurosci 2013;263:159‑65.
antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 57. Brambilla P, Bellani M, Isola M, Bergami A, Marinelli V, Dusi N,
2001;25:767‑80. Rambaldelli G, Tansella M, Finardi AM, Martino G, Perlini C,
38. Maes M. Depression is an inflammatory disease, but cell‑mediated Furlan R. Increased M1/decreased M2 signature and signs of Th1/
immune activation is the key component of depression. Prog Th2 shift in chronic patients with bipolar disorder, but not in those
Neuropsychopharmacol Biol Psychiatry 2011;35:664‑75. with schizophrenia. Transl Psychiatry 2014;4:e406.
39. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: 58. Breunis MN, Kupka RW, Nolen WA, Suppes T, Denicoff KD,
inflammation and the pathogenesis of depression. Trends Immunol Leverich GS, Post RM, Drexhage HA. High numbers of circulating
2006;27:24‑31. activated T cells and raised levels of serum IL‑2 receptor in bipolar
40. Sperner‑Unterweger B, Kohl C, Fuchs D. Immune changes and disorder. Biol Psychiatry 2003;53:157‑65.
neurotransmitters: possible interactions in depression? Prog 59. Brietzke E, Kauer‑Sant’Anna M, Teixeira AL, Kapczinski F.
Neuropsychopharmacol Biol Psychiatry 2014;48:268‑76. Abnormalities in serum chemokine levels in euthymic patients with
41. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation bipolar disorder. Brain Behav Immun 2009;23:1079‑82.
and the phenomenology, pathophysiology, comorbidity, and 60. Brown NC, Andreazza AC, Young LT. An updated meta‑analysis
treatment of bipolar disorder: a systematic review of the literature. of oxidative stress markers in bipolar disorder. Psychiatry Res
J Clin Psychiatry 2009;70:1078‑90. 2014;218:61‑8.
42. Basanth KK, Jacob R, Jacob KS. Mania associated with interferon 61. Chung KH, Huang SH, Wu JY, Chen PH, Hsu JL, Tsai SY. The link
alpha2b treatment. J Postgrad Med 2006;52:207‑9. between high‑sensitivity C‑reactive protein and orbitofrontal cortex
43. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, in euthymic bipolar disorder. Neuropsychobiology 2013;68:168‑73.
Mihm MA, Tanabe KK, Ott M, Haluska FG. Adjuvant therapy of 62. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A,
melanoma with interferon‑alpha‑2b is associated with mania and Nolen WA, Drexhage HA. The activation of monocyte and T cell
bipolar syndromes. Cancer 2000;89:356‑62. networks in patients with bipolar disorder. Brain Behav Immun
44. Mazzone L, Mugno D. Hypomanic mood in a child patient treated 2011;25:1206‑13.
with interferon‑alpha 2a: case report. Brain Dev 2007;29:666‑9. 63. Huang TL, Lin FC. High‑sensitivity C‑reactive protein levels in
45. Strite D, Valentine AD, Meyers CA. Manic episodes in two patients patients with major depressive disorder and bipolar mania. Prog
treated with interferon alpha. J Neuropsychiatry Clin Neurosci Neuropsychopharmacol Biol Psychiatry 2007;31:370‑2.
1997;9:273‑6. 64. Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ,
46. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, de Ridder D, Kupka RW, Nolen WA, Drexhage HA. A discriminating
Demotes‑Mainard J, Henry C. Mood alterations during interferon‑alfa messenger RNA signature for bipolar disorder formed by an
therapy in patients with chronic hepatitis C: evidence for an overlap aberrant expression of inflammatory genes in monocytes. Arch Gen
between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2008;65:395‑407.
Psychiatry 2005;66:1050‑7. 65. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity
47. Dell’Osso L, Pini S, Maggi L, Rucci P, Del Debbio A, Carlini M, and neuroinflammatory markers in postmortem frontal cortex from
Baldini A, Ferrari G, Manca E, Beverini E, Amore M, Scarallo V, bipolar disorder patients. Mol Psychiatry 2010;15:384‑92.
Semeraro Q, Brunetto M, Bonino F, Maj M. Subthreshold mania as 66. Stertz L, Magalhaes PV, Kapczinski F. Is bipolar disorder an
predictor of depression during interferon treatment in HCV+patients inflammatory condition? The relevance of microglial activation.
without current or lifetime psychiatric disorders. J Psychosom Res Curr Opin Psychiatry 2013;26:19‑26.
2007;62:349‑55. 67. Watkins CC, Sawa A, Pomper MG. Glia and immune cell signaling
48. Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, in bipolar disorder: insights from neuropharmacology and molecular
Conigliaro J, Haas GL. Burden of general medical conditions among imaging to clinical application. Transl Psychiatry 2014;4:e350.
individuals with bipolar disorder. Bipolar Disord 2004;6:368‑73. 68. Bai YM, Su TP, Tsai SJ, Wen‑Fei C, Li CT, Pei‑Chi T, Mu‑Hong C.
49. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA Comparison of inflammatory cytokine levels among type I/type II
2005;293:2528‑30. and manic/hypomanic/euthymic/depressive states of bipolar
50. Sharma AN, Bauer IE, Sanches M, Galvez JF, Zunta‑Soares GB, disorder. J Affect Disord 2014;166:187‑92.
Quevedo J, Kapczinski F, Soares JC. Common biological 69. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations
mechanisms between bipolar disorder and type 2 diabetes: focus in bipolar disorder: a meta‑analysis of 30 studies. Biol Psychiatry
on inflammation. Prog Neuropsychopharmacol Biol Psychiatry 2013;74:15‑25.
2014;54:289‑98. 70. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in
51. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, bipolar disorder vs. healthy control subjects: a systematic review
Kupfer DJ. Can bipolar disorder be viewed as a multi‑system and meta‑analysis. J Psychiatr Res 2013;47:1119‑33.
inflammatory disease? J Affect Disord 2012;141:1‑10. 71. Borsini A, Zunszain PA, Thuret S, Pariante CM. The role of

222 Neuroimmunol Neuroinflammation | Volume 2 | Issue 4 | October 15, 2015